Newer treatments for decompensated heart failure: focus on levosimendan
Ferenc FollathUniversity Hospital Zürich, Steering Group Drug Therapy, Zürich, SwitzerlandAbstract: Acute heart failure (AHF) is a major cause of hospitalizations. Severe dyspnea, pulmonary congestion and low cardiac output with peripheral vasoconstriction and renal hypoper...
Main Author: | Ferenc Follath |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-03-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/newer-treatments-for-decompensated-heart-failure-focus-on-levosimendan-a2940 |
Similar Items
-
Role of Levosimendan in acute decompensated heart failure
by: V.K. Katyal, et al.
Published: (2021-12-01) -
IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE
by: M. V. Lediakhova, et al.
Published: (2018-05-01) -
Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
by: William Juguet, et al.
Published: (2020-11-01) -
Podemos acreditar na levosimendana? Can we believe in levosimendan?
by: Ferenc Follath
Published: (2008-03-01) -
Levosimendana em pacientes com insuficiência cardíaca descompensada Levosimendan in patients with decompensated heart failure
by: Eduardo Maffini da Rosa, et al.
Published: (2008-08-01)